Get notified of page updates

Search Results: Treatment + Ovarian Cancer (3 results)

New Search
PRINTER FRIENDLY PAGE 1 through 3 of 3

Treatment
Phase 3 treatment study for platinum-resistant ovarian cancer

Comparing an Investigational Targeted Drug AZD5335 to Standard Treatments in People With Platinum‑Resistant Ovarian Cancer (TREVI‑OC‑01)

This study is testing whether a new targeted therapy called AZD5335 works better than currently used treatments for people with platinum‑resistant ovarian, fallopian tube, or primary peritoneal cancer.The study is looking at how long people live without their cancer getting worse while taking AZD5335 compared with standard treatments. 

Clinicaltrials.gov identifier: NCT07218809

Treatment
Treatment study for people with advanced solid tumors

Study of a New Investigational Inhibitor to Treat People with Advanced Solid Tumors

The study will test if an investigational treatment, XL309, is safe and works when used alone or in combination with a PARP inhibitor to treat people with some advanced solid tumors. The study is enrolling people with BRCA1 or BRCA2 inherited mutations and have HER2-negative breast cancer, prostate cancer, pancreatic cancer, high grade ovarian, fallopian tube or primary peritoneal cancer; or other solid tumors with certain genetic mutations. 

Clinicaltrials.gov identifier: NCT05932862

Treatment
Treatment study for people with advanced or metastatic solid tumors

Treating Advanced or Metastatic Cancers with a New PARP1 Inhibitor (GS-0201) Alone or Combined with Other Drugs

The goal of this treatment study is to learn if the new drug GS-0201 is safe and can help treat people with different types of metastatic or advanced cancer. GS-0201 is a new drug that has not yet been approved for treatment of cancer. GS-0201 is a type of targeted therapy known as a PARP1 inhibitor. 

Clinicaltrials.gov identifier: NCT06167317
Additional Results on Clinicaltrials.gov Treatment + Ovarian Cancer + parp
11 results
Clinical Trial Official Title
NCT07504588 Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy
NCT05797168 Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
NCT05564377 Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
NCT04606914 Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
NCT05123482 A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
NCT05942300 CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer
NCT04633239 Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer
NCT06580314 Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
NCT06856499 Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer
NCT04585958 Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer
NCT04701645 Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer

Sponsored By